ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced the commencement of a Phase Ib study for its innovative dual-target macromolecular drug, amulirafusp alfa (IMM0306), in patients with neuromyelitis optica spectrum disorders (NMOSD). This marks a significant step as the first patient has been dosed in the study.
Amulirafusp Alfa: A Pioneering Bispecific Antibody for NMOSD
Amulirafusp alfa (IMM0306) is a bispecific antibody (BsAb) that targets cluster of differentiation 47 (CD47) and CD20. It is the first drug of its kind to enter clinical evaluation globally. This development highlights ImmuneOnco’s commitment to pioneering therapies for complex diseases. The drug’s unique dual-target mechanism offers potential for significant therapeutic benefits in NMOSD, a rare autoimmune disease that affects the optic nerves and spinal cord.
Regulatory Clearance and Ongoing Developments
Earlier this month, amulirafusp alfa received clearance for a Phase II study in lupus nephritis (LN) in China, indicating the drug’s broad potential applications in treating autoimmune conditions. The initiation of the Phase Ib study for NMOSD further expands the drug’s clinical development program, showcasing ImmuneOnco’s dedication to advancing novel treatments for severe diseases with unmet medical needs.-Fineline Info & Tech
Leave a Reply